A high affinity, selective inhibitor of Rho family GTPases with EC50 of 16-120 uM.

A heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro.

A heterobifunctional small molecule PROTAC capable of cereblon mediated proteasomal degradation of CDK9.

A heterobifunctional cross-linking reagent incorporating an extended spacer with amine and sulfhydryl reactivity.

A herbicide safener for gramineous crops..

A herbicide agent. .

A HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2.

A HDAC inhibitor that selectively inhibits the catalytic activity of class I HDACs, and induces proteasomal degradation of HDAC2.

A glycyrrhetinic acid derivative that inhibits 11β-hydroxysteroid dehydrogenase (11β-HSD), a gap junction blocker and mineralocorticoid agonist..

A glycyrrhetinic acid derivative that inhibits 11β-hydroxysteroid dehydrogenase (11β-HSD), a gap junction blocker and mineralocorticoid agonist..

A galactose analogue that is an UDP-glucose ceramide glucosyltransferase (UGCG/GCS) inhibitor (IC50=41.4 uM).

A gain-of-function ligand for PGRMC2 (progesterone receptor membrane component 2) to promote adipogenesis.

A GABA transport inhibitor with IC50 of 5, 21, 388 and 140 uM for hGAT-3, rGAT-2, hGAT-1 and BGT-1, respectively.

A GABA receptor agonist and modulator of glutamatergic systems.

A fungal natural product that binds to HuR and inhibits HuR-RNA interaction in vitro with IC50 of 1.2 uM.

A fucose analog that inhibits Dll-induced Notch signaling by reducing Notch ligand Dll1-Notch1 binding, but not Jag1.

A fourth-generation fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase and topoisomerase IV.

A fourth-generation fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase and topoisomerase IV.

A fourth-generation fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase and topoisomerase IV.

A form of dynorphin and an endogenous opioid peptide with the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys..

A first-in-class, small molecule protein-protein inhibitor of the interaction between the E1 and E2 proteins of HPV types 6 and 11.

A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively.

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class antitumor and antimetastatic agent that induces necrosis in breast cancer tumors, inhibits inhibit mitochondria complex I activity and reduces HIF-1α stabilization.

A first-generation antihistamine that acts primarily as H1 receptor antagonist.

A dual inhibitor of TNF-α and TGF-β1 by inhibiting IκB kinase phosphorylation and Smad3 phosphorylation.

A dual inhibitor of E selectin and CXCR4 with IC50 of 4.1 uM and 30 nM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice.

A dual inhibitor of E selectin and CXCR4 with IC50 of 3.6 uM and 1.1 uM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice.